X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs UNICHEM LAB - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA UNICHEM LAB AUROBINDO PHARMA/
UNICHEM LAB
 
P/E (TTM) x 20.8 -33.1 - View Chart
P/BV x 3.9 0.7 544.5% View Chart
Dividend Yield % 0.3 2.4 13.6%  

Financials

 AUROBINDO PHARMA   UNICHEM LAB
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
UNICHEM LAB
Mar-18
AUROBINDO PHARMA/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs809382 211.8%   
Low Rs504234 215.3%   
Sales per share (Unadj.) Rs281.1116.3 241.7%  
Earnings per share (Unadj.) Rs41.4-18.9 -218.6%  
Cash flow per share (Unadj.) Rs50.9-11.7 -433.4%  
Dividends per share (Unadj.) Rs2.505.00 50.0%  
Dividend yield (eoy) %0.41.6 23.5%  
Book value per share (Unadj.) Rs199.4381.0 52.3%  
Shares outstanding (eoy) m585.8870.34 832.9%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x2.32.6 88.2%   
Avg P/E ratio x15.9-16.3 -97.5%  
P/CF ratio (eoy) x12.9-26.2 -49.2%  
Price / Book Value ratio x3.30.8 407.3%  
Dividend payout %6.0-26.4 -22.9%   
Avg Mkt Cap Rs m384,63021,668 1,775.1%   
No. of employees `00017.32.3 760.2%   
Total wages/salary Rs m21,3082,006 1,062.0%   
Avg. sales/employee Rs Th9,500.73,587.8 264.8%   
Avg. wages/employee Rs Th1,229.4880.0 139.7%   
Avg. net profit/employee Rs Th1,397.9-583.7 -239.5%   
INCOME DATA
Net Sales Rs m164,6668,180 2,013.0%  
Other income Rs m1,020610 167.2%   
Total revenues Rs m165,6868,790 1,884.9%   
Gross profit Rs m37,718-1,320 -2,857.0%  
Depreciation Rs m5,580505 1,104.7%   
Interest Rs m77780 970.3%   
Profit before tax Rs m32,380-1,295 -2,499.8%   
Minority Interest Rs m310-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,18333 24,484.4%   
Profit after tax Rs m24,229-1,331 -1,820.5%  
Gross profit margin %22.9-16.1 -141.9%  
Effective tax rate %25.3-2.6 -979.4%   
Net profit margin %14.7-16.3 -90.4%  
BALANCE SHEET DATA
Current assets Rs m121,87823,318 522.7%   
Current liabilities Rs m86,8064,635 1,872.8%   
Net working cap to sales %21.3228.4 9.3%  
Current ratio x1.45.0 27.9%  
Inventory Days Days130122 106.7%  
Debtors Days Days68121 56.3%  
Net fixed assets Rs m81,0378,163 992.7%   
Share capital Rs m586141 416.4%   
"Free" reserves Rs m116,21826,660 435.9%   
Net worth Rs m116,80426,801 435.8%   
Long term debt Rs m4,5123 136,727.3%   
Total assets Rs m211,05231,890 661.8%  
Interest coverage x42.7-15.2 -281.2%   
Debt to equity ratio x00 31,372.2%  
Sales to assets ratio x0.80.3 304.2%   
Return on assets %11.8-3.9 -302.1%  
Return on equity %20.7-5.0 -417.7%  
Return on capital %27.4-4.5 -602.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m80,7274,356 1,853.1%   
Fx outflow Rs m34,7000-   
Net fx Rs m46,0274,356 1,056.5%   
CASH FLOW
From Operations Rs m19,548-1,123 -1,740.1%  
From Investments Rs m-19,57016,487 -118.7%  
From Financial Activity Rs m8,642-8,811 -98.1%  
Net Cashflow Rs m8,9226,552 136.2%  

Share Holding

Indian Promoters % 54.1 50.1 108.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 15.1 52.6%  
FIIs % 27.7 3.0 923.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 31.7 32.2%  
Shareholders   69,601 20,176 345.0%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   SANOFI INDIA  TORRENT PHARMA  PLETHICO PHARMA  CIPLA  ABBOTT INDIA  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Brexit Deal; Key Q2FY19 Results & Top Stocks in Focus Today(Pre-Open)

On Thursday, Indian share markets ended marginally higher led by bank stocks and finance stocks. At the closing bell, the BSE Sensex ended up by 119 points.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

UNICHEM LAB Announces Quarterly Results (2QFY19); Net Profit Down 61.4% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, UNICHEM LAB has posted a net profit of Rs 177 m (down 61.4% YoY). Sales on the other hand came in at Rs 2 bn (down 42.6% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

Which Equity Mutual Funds to Buy Now?(Outside View)

Nov 13, 2018

PersonalFN explains that in falling markets investing in equity mutual funds can be beneficial in long run by choosing the right equity mutual fund scheme.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Nov 15, 2018 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - TTK HEALTHCARE COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS